USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
HEMOSHEAR, LLC
Address:
1115 5TH ST SW
CHARLOTTESVILLE, VA 22902-6465
Phone:
N/A
URL:
N/A
EIN:
126197923
DUNS:
809452217
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,187,118.00 5
SBIR Phase II $5,878,029.00 2

Award List:

Genome-wide profiling of human vascular response to oxidized lipoprotreins

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$166,830.00
Agency:
HHS
Principal Investigator:
Brett R. Blackman
Abstract:
DESCRIPTION (provided by applicant): Atherosclerosis is a vascular inflammatory disease characterized by dramatic changes in endothelial cell (EC) and smooth muscle cell (SMC) phenotypes. The progression of atherosclerosis is dependent on interactions bet ween vascular cells (EC/SMC), regional… More

Hemodynamic Co-Culture Liver Model for Drug Discovery and Assessment

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$190,786.00
Agency:
HHS
Principal Investigator:
Brett R. Blackman – 434-872-0198
Abstract:
DESCRIPTION (provided by applicant): Drug developers desperately need better tools in the laboratory to improve the 90% failure rate of drugs in clinical trials. Liver toxicity is still the leading cause of drug failure, despite extensive preclinical testing in surrogate animal species. HemoShear… More

Creating a predictive vascular system for early development

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$4,293,883.00
Agency:
HHS
Principal Investigator:
Brett R. Blackman – 434-872-0198
Abstract:
DESCRIPTION (provided by applicant): The frequent inability of in vitro assays and animal models to accurately predict human response to a new drug candidate results in costly drug development failures. HemoShear has developed a platform technology for biodiscovery and drug pharmacology screening… More

Development of a human hepatocyte predictive pharmacology and toxicology system.

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$1,584,146.00
Agency:
HHS
Principal Investigator:
Brian R. Wamhoff – 434-872-0198
Abstract:
DESCRIPTION (provided by applicant): There is a critical need to improve the accuracy of preclinical drug efficacy and toxicity screening and testing through the development of human hepatocyte (liver) in vitro culture systems that more effectively mimic the human in vivo environment. HemoShear is a… More

TOPIC 314: DEVELOPMENT OF HUMAN TISSUE CULTURE SYSTEM THAT MIMICS THE TUMOR MICRO

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$298,547.00
Agency:
HHS
Principal Investigator:
Dr B. Wamhoff – 434-760-2720
Abstract:
Not Available

Development of an iPSC-derived human vascular system for drug discovery and devel

Award Year / Program / Phase:
2014 / SBIR / Phase I
Award Amount:
$249,013.00
Agency:
HHS
Principal Investigator:
Brian R. Wamhoff – 434-872-0198
Abstract:
DESCRIPTION (provided by applicant): R43 SBIR: Development of an iPSC-derived human vascular system for drug development. ABSTRACT Human inducible pluripotent stem cells (iPSCs) can be differentiated into vascular endothelial (iEC) and smooth muscle (iSMC)cells and hold immense potential for… More

Development of an iPSC-derived human hepatocyte platform for drug development.

Award Year / Program / Phase:
2014 / SBIR / Phase I
Award Amount:
$281,942.00
Agency:
HHS
Principal Investigator:
Brian R. Wamhoff – 434-872-0198
Abstract:
DESCRIPTION (provided by applicant): Human inducible pluripotent stem cells (iPSCs) proliferate readily and can be terminally differentiated into hepatocytes, which potentially makes them an attractive, cost-effective resource compared to primary human hepatocytes. Moreover, the ability to… More